Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers;...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of IMMX is 9.2 and suggests 71% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell